News | September 17, 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Total investment incurred for setting up the new R&D Rs 250 crore
GPCB has also asked to submit a bank guarantee of Rs. 2, 00,000 for compliance assurance at the time of revocation and has also ordered to deposit interim environment damage compensation amount
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
The acquisition is based on an enterprise value of Rs. 1,660 crore
Subscribe To Our Newsletter & Stay Updated
